Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMN047
MIFTS: 53

Human Cytomegalovirus Infection

Categories: Infectious diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Human Cytomegalovirus Infection

About this section

MalaCards integrated aliases for Human Cytomegalovirus Infection:

Name: Human Cytomegalovirus Infection 11 14
Cytomegalovirus Infection 28 2 16
Cytomegalovirus Infections 41 71

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:0080827
UMLS 71 C0010823
Sources

Summaries for Human Cytomegalovirus Infection

About this section

MedlinePlus: 41 Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50% and 80% of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems. But some babies can develop lifelong disabilities. A blood test can tell whether a person has ever been infected with CMV. Most people with CMV don't need treatment. If you have a weakened immune system, your doctor may prescribe antiviral medicine. Good hygiene, including proper hand washing, may help prevent infections. Centers for Disease Control and Prevention

MalaCards based summary: Human Cytomegalovirus Infection, also known as cytomegalovirus infection, is related to toxoplasmosis and chorioretinitis, and has symptoms including fever and pruritus. An important gene associated with Human Cytomegalovirus Infection is STX5 (Syntaxin 5), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Azathioprine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and kidney, and related phenotypes are nervous system and no phenotypic analysis

CDC: 2 Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. When a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. About one out of every 200 babies is born with congenital CMV infection. About one in five babies with congenital CMV infection will have long-term health problems.

Disease Ontology: 11 A viral infectious disease that has material basis in Human betaherpesvirus 5.
Sources

Related Diseases for Human Cytomegalovirus Infection

About this section

Diseases related to Human Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1449)
# Related Disease Score Top Affiliating Genes
1 toxoplasmosis 31.2 TNF IL6 IL17A
2 chorioretinitis 30.9 TNF IL6 IL17A CD8A CD4 CCR6
3 gastritis 30.9 TNF IL6 IL17A CCR6
4 esophagitis 30.9 TNF IL6 EGFR
5 bronchiolitis 30.8 TNF IL6 IL17A
6 rubella 30.8 TNF IL6 IFNB1
7 bronchiolitis obliterans 30.8 TNF IL6 IL17A
8 adult t-cell leukemia/lymphoma 30.7 CD8A CD4 CCR6
9 cystitis 30.7 TNF IL6 IL17A
10 encephalitis 30.7 TNF RSAD2 IL6 IFNB1
11 bilirubin metabolic disorder 30.7 TNF IL6 CD8A CD4
12 pneumocystosis 30.7 TNF IL6 IL17A CD8A CD4 CCR6
13 congenital toxoplasmosis 30.6 TNF CD8A CD4
14 herpes simplex 30.6 RSAD2 IFNB1 GYPC CD8A
15 deficiency anemia 30.6 TNF IL6 CD8A CD4 CCR6
16 purpura 30.6 TNF IL6 IL17A
17 granulomatous hepatitis 30.6 TNF CD8A CD4
18 hemophagocytic lymphohistiocytosis 30.6 TNF IL6 CD8A CD4 CCR6
19 perinatal necrotizing enterocolitis 30.6 TNF IL6 IL17A CD4 CCR6
20 pericardial effusion 30.6 TNF IL6 CD4
21 leukemia, acute lymphoblastic 30.6 MIR199A1 KIR3DL1 CD8A CD4 CCR6
22 diarrhea 30.5 TNF IL6 IFNB1 EGFR
23 arteries, anomalies of 30.5 TNF MIR199A1 IL6 CCR6
24 intestinal perforation 30.5 TNF IL6 CD8A CD4 CCR6
25 sialadenitis 30.5 TNF CD4 CCR6
26 exanthem 30.5 TNF IL6 IL17A EGFR CD8A CD4
27 anemia, autoimmune hemolytic 30.5 IL6 CD8A CD4 CCR6
28 combined immunodeficiency 30.5 TNF IL6 IL17A CD8A CD4 CCR6
29 inflammatory bowel disease 1 30.5 TNF IL6 IL17A CCR6
30 thrombocytopenia due to platelet alloimmunization 30.5 CD8A CD4 CCR6
31 pharyngitis 30.4 TNF IL6 CD8A CD4 CCR6
32 thrombocytopenic purpura, autoimmune 30.4 CD8A CD4 CCR6
33 duodenitis 30.4 TNF CD8A CD4
34 ileus 30.4 TNF IL6 IL17A
35 legionnaire disease 30.4 TNF IL6 CD4
36 hemorrhagic cystitis 30.4 TNF IL6 CD8A CD4
37 demyelinating polyneuropathy 30.4 TNF IL6 CD8A CD4
38 adult-onset still's disease 30.4 TNF IL6 CCR6
39 cryptosporidiosis 30.4 TNF CD8A CD4
40 aortic aneurysm, familial abdominal, 1 30.4 TNF MIR199A1 IL6 CCR6
41 ulcerative colitis 30.3 TNF IL6 IL17A CCR6
42 syphilis 30.3 TNF IL17A CD8A CD4 CCR6
43 henoch-schoenlein purpura 30.3 TNF IL6 CD4 CCR6
44 pneumonia 30.3 TNF IL6 IL17A CD8A
45 portal hypertension 30.3 TNF MIR199A1 CCR6
46 histiocytosis 30.3 TNF IL17A CCR6
47 dermatitis 30.3 TNF IL6 IL17A CCR6
48 juvenile rheumatoid arthritis 30.3 TNF IL6 CD4 CCR6
49 chlamydia 30.3 TNF IL6 IL17A
50 myelitis 30.3 TNF IL6 IL17A IFNB1 CCR6

Comorbidity relations with Human Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Human Cytomegalovirus Infection:



Diseases related to Human Cytomegalovirus Infection
Sources

Symptoms & Phenotypes for Human Cytomegalovirus Infection

About this section

UMLS symptoms related to Human Cytomegalovirus Infection:


fever; pruritus

MGI Mouse Phenotypes related to Human Cytomegalovirus Infection:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.93 B3GAT1 CCR6 CD4 CD8A EGFR HLA-E
2 no phenotypic analysis MP:0003012 9.86 CD4 EGFR HLA-E IFNB1 IL17A KLRD1
3 immune system MP:0005387 9.8 CCR6 CD4 CD8A EGFR HLA-E IFNB1
4 hematopoietic system MP:0005397 9.47 CCR6 CD4 CD8A EGFR GYPC HLA-E
Sources

Drugs & Therapeutics for Human Cytomegalovirus Infection

About this section

Drugs for Human Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
5
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
6
Basiliximab Approved, Investigational Phase 4 179045-86-4
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
11
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
12
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
13
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
14
Metamizole Approved, Investigational, Withdrawn Phase 4 50567-35-6 3111 522325
15
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
16
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
17
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
18
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
19
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
20
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
21
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
22
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
23
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
24
Letermovir Approved, Investigational Phase 4 917389-32-3 9916099 45138674
25
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
26
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
27
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
28
Valaciclovir Approved, Investigational Phase 4 124832-27-5, 124832-26-4 60773 135398742
29
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
30
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
31 Antifungal Agents Phase 4
32 Pharmaceutical Solutions Phase 4
33 Hormones Phase 4
34 Hormone Antagonists Phase 4
35
Methylprednisolone Acetate Phase 4 584547
36 Calcineurin Inhibitors Phase 4
37 Hydrocortisone 17-butyrate 21-propionate Phase 4
38 Antineoplastic Agents, Hormonal Phase 4
39 Gastrointestinal Agents Phase 4
40 Neuroprotective Agents Phase 4
41 Antiemetics Phase 4
42 Protective Agents Phase 4
43 Anti-Arrhythmia Agents Phase 4
44 Calcium, Dietary Phase 4
45 Anticonvulsants Phase 4
46 calcium channel blockers Phase 4
47 Anesthetics Phase 4
48 Analgesics Phase 4
49 Tocolytic Agents Phase 4
50 Reverse Transcriptase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 302)
# Name Status NCT ID Phase Drugs
1 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus) Unknown status NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
2 An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients. Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
3 Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients. Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
4 The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
5 Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
6 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
7 A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®). Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
8 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus
9 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients Completed NCT01552369 Phase 4 Valganciclovir
10 A Randomized, Open-label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
11 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
12 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
13 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
14 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
15 A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls Completed NCT01663740 Phase 4 Valganciclovir
16 Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
17 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
18 A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT) Completed NCT02550639 Phase 4
19 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir : Prospective Multicenter Nonrandomized Trial Completed NCT01651585 Phase 4 Valacyclovir arrow
20 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection Completed NCT01509404 Phase 4 Valganciclovir
21 Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
22 Phase IV Clinical Trial, Open, Randomized, Controlled and Multicentric, With Two Parallel Groups, to Assess the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients, Based on the Specific Basal T Cell Response Against Cytomegalovirus: ELISPOT-TC Recruiting NCT04278547 Phase 4
23 Evaluation of the Tolerability and Clinical Effectiveness of Letermovir in Heart Transplantation Recruiting NCT04904614 Phase 4 Letermovir
24 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
25 A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients Not yet recruiting NCT05626530 Phase 4 Letermovir
26 Effect of the Introduction of mTor Inhibitors in the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response to Control Viral Replication in Kidney Transplant Patients Not yet recruiting NCT04936971 Phase 4 Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm
27 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir: Prospective Multicenter Randomized Trial Versus Placebo Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
28 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
29 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Withdrawn NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
30 Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
31 Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection Unknown status NCT02787382 Phase 3
32 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Completed NCT01376778 Phase 3 CMV hyperimmune globulin
33 A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112) Completed NCT00466817 Phase 3 Valganciclovir
34 A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
35 Participation of Cytomegalovirus Infection or an Autoimmune Process in T Lymphocyte Activation of HIV-1 Infected Patients With Undetectable Viral Load on Antiretroviral Therapy. Completed NCT04067869 Phase 3
36 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
37 A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation. Completed NCT00275665 Phase 3 Valganciclovir
38 A Phase 3, Open-Label, Single-Arm Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of MK-8228 (Letermovir) for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients Completed NCT04129398 Phase 3 Letermovir tablet;Letermovir IV
39 The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group Completed NCT02005822 Phase 3 Valganciclovir
40 Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
41 A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant Completed NCT01077908 Phase 3 Best available antiviral drug therapy
42 Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Completed NCT02351102 Phase 2, Phase 3 Valacyclovir;Placebo
43 A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT) Completed NCT03930615 Phase 3 Letermovir;Placebo
44 A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants. Completed NCT00411645 Phase 3 maribavir
45 A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants Completed NCT00497796 Phase 3 maribavir;ganciclovir
46 A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration Completed NCT00372229 Phase 3 Valganciclovir CMV Prophylaxis;Valganciclovir (Pre-emptive CMV Therapy);Ganciclovir
47 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
48 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
49 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients Completed NCT00294515 Phase 3 Valganciclovir
50 Phase III Study Evaluating the Safety and Efficacy of Artesunate in Preemptive Treatment of Human Cytomegalovirus Disease in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate

Search NIH Clinical Center for Human Cytomegalovirus Infection

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cidofovir
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Cytomegalovirus Pyrophosphate Analog DNA Polymerase Inhibitor [EPC]
Foscarnet
Foscarnet Sodium Hexahydrate
Ganciclovir
Ganciclovir Sodium
Immunoglobulins, Intravenous
valganciclovir
Valganciclovir hydrochloride
Sources

Genetic Tests for Human Cytomegalovirus Infection

About this section

Genetic tests related to Human Cytomegalovirus Infection:

# Genetic test Affiliating Genes
1 Cytomegalovirus Infection 28
Sources

Anatomical Context for Human Cytomegalovirus Infection

About this section

Organs/tissues related to Human Cytomegalovirus Infection:

MalaCards : T Cells, Bone Marrow, Kidney, Liver, Heart, Lung, Bone
Sources

Publications for Human Cytomegalovirus Infection

About this section

Articles related to Human Cytomegalovirus Infection:

(show top 50) (show all 10190)
# Title Authors PMID Year
1
Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study. 41
36463264 2022
2
Rapid identification of CMV-specific TCRs via reverse TCR cloning system based on bulk TCR repertoire data. 41
36466875 2022
3
Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. 41
36458000 2022
4
The association between congenital cytomegalovirus infection and cerebral palsy: A systematic review and meta-analysis. 62
36250689 2022
5
Neurological evaluation of microcephalic children with Zika syndrome and congenital cytomegalovirus infection. 62
36164338 2022
6
In silico analysis of genomic landscape of SARS-CoV-2 and its variant of concerns (Delta and Omicron) reveals changes in the coding potential of miRNAs and their target genes. 62
36470485 2022
7
Cytomegalovirus DNA detection in pregnant women with a high IgG avidity index: a valuable tool for diagnosing non-primary infections? 62
35139746 2022
8
Congenital cytomegalovirus infection: do pregnant women and healthcare providers know enough? A systematic review. 62
33944654 2022
9
Ventricular septal defect and aortic hypoplasia in congenital cytomegalovirus infection: occasional finding or underdetected correlation? 62
33910458 2022
10
Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data. 62
35633464 2022
11
Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody-associated vasculitis: A narrative review. 62
36135777 2022
12
Congenital cytomegalovirus infection in newborns born to HIV-infected mothers. 62
36274043 2022
13
Cutting Edge: CCR9 Promotes CD8+ T Cell Recruitment to the Brain during Congenital Cytomegalovirus Infection. 62
36469843 2022
14
Association of Cytomegalovirus Infection with Lenticulostriate Stroke After Mild Head Trauma in Young Children. 62
35118892 2022
15
Meeting Report: Third International Congress of the International Society of Uterus Transplantation, Tübingen. 62
36436097 2022
16
Letermovir and tacrolimus interaction effects in hematopoietic cell transplantation recipients receiving moderate cytochrome P450 3A4 inhibitors for antifungal prophylaxis. 62
36398324 2022
17
Cytomegalovirus-Associated Gianotti-Crosti Syndrome in 28-Year-Old Immunocompetent Patient. 62
36422590 2022
18
The Histopathology of Anorectal Neisseria gonorrhoeae Infection. 62
35938627 2022
19
[Correlation between serum IgM antibody and viral load with clinical symptoms in neonates infected with cytomegalovirus]. 62
36372757 2022
20
Is CMV PCR of inner ear fluid during cochlear implantation a way to diagnose CMV-related hearing loss? 62
36369401 2022
21
Neonatal and long-term outcomes of infants with congenital cytomegalovirus infection and negative amniocentesis: systematic review and meta-analysis. 62
36412976 2022
22
New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of EBMT. 62
36396949 2022
23
Cutting Edge: CCR9 Promotes CD8+ T Cell Recruitment to the Brain during Congenital Cytomegalovirus Infection. 62
36344110 2022
24
Cytomegalovirus infection is associated with rapid NK differentiation and reduced incidence of relapse in HLA matched sibling donor transplant patients. 62
36383237 2022
25
Perinatal Cytomegalovirus Infection. 62
36465883 2022
26
Indirect effects of cytomegalovirus infection: Implications for vaccine development. 62
36378563 2022
27
Cortical maturation assessed by magnetic resonance imaging in unaffected/mildly affected fetuses with cytomegalovirus infection. 62
36349881 2022
28
Diagnostic test accuracy of PCR by saliva specimen for cytomegalovirus infection in newborn: A protocol for systematic review and meta-analysis. 62
36451507 2022
29
Congenital cytomegalovirus infection with brainstem hemorrhage and polymicrogyria: Necropsic and histopathological findings. 62
35941838 2022
30
Maribavir (Livtencity) for cytomegalovirus infection. 62
36397194 2022
31
Are We Aware of the Neurological Manifestations of Cytomegalovirus Infection in Immunocompetent Individuals? 62
35302054 2022
32
Cytomegalovirus infection reduced CD70 expression, signaling and expansion of viral specific memory CD8+ T cells in healthy human adults. 62
36368988 2022
33
Impact of cytomegalovirus infection prior to hematopoietic stem cell transplantation in children with inborn errors of immunity. 62
36102997 2022
34
T-lymphocyte subtyping: an early warning and a potential prognostic indicator of active cytomegalovirus infection in patients with sepsis. 62
36106958 2022
35
Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation. 62
36054234 2022
36
Congenital cytomegalovirus infection is associated with congenital rickets: a retrospective autopsy cohort study. 62
36379699 2022
37
Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. 62
35993155 2022
38
Death from human cytomegalovirus infection in a girl with congenital thymic dysplasia. 62
36348432 2022
39
A systematic review and meta-analysis of the prevalence of human cytomegalovirus shedding in seropositive pregnant women. 62
36196755 2022
40
MORC3 restricts human cytomegalovirus infection by suppressing the major immediate-early promoter activity. 62
35879101 2022
41
Human cytomegalovirus infection of epithelial cells increases SARS-CoV-2 superinfection by upregulating the ACE2 receptor. 62
36408607 2022
42
[Intestinal pseudo-obstruction: An infrequent manifestation of cytomegalovirus infection]. 62
36253305 2022
43
Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States. 62
36126024 2022
44
Audiovestibular Consequences of Congenital Cytomegalovirus Infection: Greater Vulnerability of the Vestibular Part of the Inner Ear. 62
35687026 2022
45
[Cytomegalovirus associated myelitis in a non-immunocompromised adult due to initial cytomegalovirus infection]. 62
36450486 2022
46
The association between late-onset keratitis in congenital cytomegalovirus infection: A nationwide population-based cohort study. 62
36343960 2022
47
Association of Serum Vitamin D with Active Human Cytomegalovirus Infections in Chinese Children with Systemic Lupus Erythematosus. 62
35908867 2022
48
Steroid Resistance/Dependence Might Be an Alarming Feature for Cytomegalovirus Infection Among Ulcerative Colitis Patients With Increased Disease Activity. 62
36337831 2022
49
A Case of Cytomegalovirus Infection With Severe Thrombocytopenia in an Infant Who Was Successfully Managed With Antiviral Therapy. 62
36426305 2022
50
The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection. 62
36287269 2022
Sources

Variations for Human Cytomegalovirus Infection

About this section
Sources

Expression for Human Cytomegalovirus Infection

About this section
Search GEO for disease gene expression data for Human Cytomegalovirus Infection.
Sources

Pathways for Human Cytomegalovirus Infection

About this section

Pathways related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.69 CCR6 CD4 CD8A HLA-E IFNB1 IL17A
2
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.58 TNF MAPK1 IL6 IL17A IFNB1 EGFR
3
Cytokine Signaling in Immune system 66
Show member pathways
 13.25 TNF RSAD2 MAPK1 IL6 IL17A IFNB1
4
PAK Pathway 64
Show member pathways
 13.24 CCR6 CD4 EGFR IL17A IL6 MAPK1
5
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.54 TNF RSAD2 MAPK1 IL6 IL17A IFNB1
6
NF-kappaB Signaling 3
12.52 TNF RSAD2 LILRB1 IL17A CD8A
7
Immune response IL-23 signaling pathway 22
Show member pathways
 12.52 TNF MAPK1 IL6 IL17A EGFR CD4
8
Toll-Like receptor Signaling Pathways 65
Show member pathways
 12.46 TNF MAPK1 IL6 IFNB1
9
IL-17 Family Signaling Pathways 65
Show member pathways
 12.23 TNF MAPK1 IL6 IL17A
10
Colorectal Cancer Metastasis 64
12.14 TNF MAPK1 IL6 EGFR
11
T-cell activation SARS-CoV-2 74
Show member pathways
 12.03 CD4 CD8A IFNB1 IL17A MAPK1 TNF
12
Spinal cord injury 74
11.95 TNF MAPK1 IL6 EGFR
13
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 66
11.93 LILRB1 KLRD1 KLRC1 KIR3DL1 HLA-E CD8A
14
IL27-mediated signaling events 61
Show member pathways
 11.86 TNF IL6 IL17A CD4
15
Th17 Differentiation 65
Show member pathways
 11.81 IL6 IL17A CD4
16
Network map of SARS-CoV-2 signaling pathway 74
Show member pathways
 11.72 IL6 IFNB1 CD8A CD4
17
Acute viral myocarditis 74
11.71 CD4 IL6 MAPK1
18
Burn wound healing 74
11.71 IFNB1 IL6 TNF
19
DAP12 interactions 66
Show member pathways
 11.7 HLA-E KLRC2 KLRD1
20
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.7 TNF KLRC2 KLRC1 IL6 CD8A CD4
21
Dendritic Cells Developmental Lineage Pathway 65
11.67 TNF IL6 IFNB1 CD8A CD4
22
Th17 cell differentiation pathway 74
11.66 MAPK1 IL6 IL17A CD4
23
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.62 TNF MAPK1 IL6
24
miRNAs involvement in the immune response in sepsis 74
11.61 TNF MIR199A1 IL6
25
NF-kB (NFkB) Pathway 67
11.54 TNF MAPK1 HLA-E CD4
26
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.51 TNF MAPK1 IL6
27
Fibrin complement receptor 3 signaling pathway 74
11.42 TNF IL6 IFNB1
28
Immune response_Role of integrins in NK cells cytotoxicity 22
11.42 HLA-E KLRC1 KLRD1 MAPK1
29
Immune response CD16 signaling in NK cells 22
Show member pathways
 11.39 TNF MAPK1 KLRD1 KLRC2 KLRC1 KIR3DL1
30
Innate Lymphoid Cells Differentiation 65
11.34 TNF KLRD1 IL17A CD8A CD4 CCR6
31
Development and heterogeneity of the ILC family 74
11.28 IL17A IL6 TNF
32
Cytokines and inflammatory response 74
11.22 TNF IL6 IFNB1 CD4
33
Prostaglandin signaling 74
11.21 TNF IL6 IL17A
34
Immune infiltration in pancreatic cancer 74
11.18 TNF IL6 IL17A
35
Ebstein-Barr virus LMP1 signaling 74
11.09 IFNB1 MAPK1 TNF
36
G-protein signaling_Rap2B regulation pathway 22
10.97 TNF MAPK1 IL6 IL17A EGFR
37
Cells and molecules involved in local acute inflammatory response 74
Show member pathways
 10.32 TNF IL6
Sources

GO Terms for Human Cytomegalovirus Infection

About this section

Cellular components related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.36 B3GAT1 CCR6 CD4 CD8A EGFR GYPC
2 membrane GO:0016020 10.36 B3GAT1 CCR6 CD4 CD8A EGFR GYPC
3 plasma membrane GO:0005887 10.13 CCR6 CD4 CD8A EGFR GYPC KIR3DL1
4 plasma membrane GO:0005886 10.13 CCR6 CD4 CD8A EGFR GYPC KIR3DL1
5 receptor complex GO:0043235 9.96 KLRD1 KLRC2 KLRC1 EGFR CD8A
6 external side of plasma membrane GO:0009897 9.6 TNF LILRB1 KLRD1 KLRC2 KLRC1 IL17A

Biological processes related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 10.21 CD4 CD8A EGFR IFNB1 KLRC1 KLRD1
2 immune response GO:0006955 10.17 TNF KIR3DL1 IL6 IL17A HLA-E CD8A
3 defense response to Gram-positive bacterium GO:0050830 10.13 TNF IL6 IL17A HLA-E
4 response to virus GO:0009615 10.05 TNF RSAD2 LILRB1 IFNB1
5 humoral immune response GO:0006959 10.03 TNF IL6 IFNB1 CCR6
6 negative regulation of viral genome replication GO:0045071 10.02 TNF RSAD2 IFNB1
7 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.97 TNF IL6 IL17A
8 positive regulation of natural killer cell mediated cytotoxicity GO:0045954 9.95 HLA-E KLRC2 KLRD1
9 adaptive immune response GO:0002250 9.89 LILRB1 KLRD1 KLRC2 KLRC1 IL17A IFNB1
10 negative regulation of T cell mediated cytotoxicity GO:0001915 9.8 LILRB1 KLRD1 KLRC1
11 natural killer cell mediated immunity GO:0002228 9.76 KLRD1 KLRC2
12 immune system process GO:0002376 9.76 CD4 CD8A HLA-E IL17A KLRC1 KLRC2
13 regulation of natural killer cell activation GO:0032814 9.73 KLRD1 KLRC2 KLRC1
14 negative regulation of cytokine production involved in immune response GO:0002719 9.71 TNF LILRB1
15 negative regulation of natural killer cell mediated cytotoxicity GO:0045953 9.17 LILRB1 KLRD1 KLRC1 HLA-E

Molecular functions related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 10.07 KLRD1 KLRC2 KLRC1 EGFR CD4
2 MHC class I protein binding GO:0042288 9.72 LILRB1 HLA-E CD8A
3 HLA-E specific inhibitory MHC class Ib receptor activity GO:0062082 9.56 KLRD1 KLRC1
4 protein antigen binding GO:1990405 9.35 KLRD1 KLRC2 KLRC1
5 HLA-B specific inhibitory MHC class I receptor activity GO:0030109 9.33 LILRB1 KIR3DL1
6 MHC class I protein complex binding GO:0023024 9.23 KLRD1 KLRC2 KLRC1 CD8A
Sources

Sources for Human Cytomegalovirus Infection

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....